Explore our core research modules engineered to eliminate knowledge gaps between lab-scale botanical discovery and industrial-scale Phase II clinical trials.
Comparative analysis of phytochemical density mapped across micro-climates, soil chemistry, and seasonal cycles.
Explore Origin Study
Full human clinical design, dose escalation, pharmacokinetics, and Phase II multicenter efficacy trials.
View Clinical Trials
GLP-compliant preclinical toxicology, acute LD50, target tissue accumulation, and disease-model validation.
Explore Animal Models
High-throughput isolation and bio-fractionation of saponins, flavonoids, and active alkaloids.
Screening Capabilities
Cellular molecular pathways, receptor-binding kinetics, and enzymatic inhibition profiles.
In Vitro Screening
HPLC, HPTLC, GC-MS, and multi-component fingerprint chromatography for cGMP batch releases.
Method Development
Controlled patient cohort verification, therapeutic window establishment, and endpoint safety validation.
Phase II Study Protocol
GMP extraction, spray drying, and pilot-to-commercial contract manufacturing for global drug innovators.
Manufacturing FacilitiesWhy modern phytopharmaceutical programs require deep end-to-end synergy between extraction chemistry and rigorous clinical protocol design.
Traditional herbal extracts routinely fail Phase II proof-of-concept trials because soil variations, seasonal harvest discrepancies, and degraded botanical secondary metabolites cause up to 40% fluctuations in biological response. MedGence institutes origin-level chromatographic mapping to stabilize the active profile before initiating dosing.
Unlike single-molecule synthesized pharmaceuticals, multi-component botanical drugs exhibit multi-target synergy. Demonstrating therapeutic dose-proportionality requires advanced In Vitro pathway profiling and preclinical pharmacokinetic modeling, preventing underdosing in human Phase II patient cohorts.
A successful Phase II proof-of-concept is valueless if the manufacturing method cannot be linearly translated into Phase III and commercial cGMP validation. Our pilot plant operates under strict non-disclosure, ensuring that process study data translates flawlessly from clinical lot releases to commercial production.
| Evaluation Parameter | Conventional Sourcing & Research | MedGence Integrated Phase II ODM Framework | Client Commercial Advantage |
|---|---|---|---|
| Raw Material Origin | Open commodity market, mixed geographical batches | Multi-season potency profiling, geolocated raw material locking | Zero fluctuation in clinical active potency |
| Analytical Validation | Basic TLC or UV spectrophotometry | HPTLC, HPLC-DAD, GC-MS, chromatographic fingerprinting | Audit-ready regulatory documentation (FDA/NMPA/EMA) |
| Preclinical Evidence | Generic literature citations | Direct GLP animal models, LD50, target in vitro bioassays | High safety margins entering Phase II trials |
| Manufacturing Scale | Fragmented contract laboratories and outside tollers | In-house 300+ scientific team from pilot to commercial cGMP | Guaranteed intellectual property ring-fencing |
Modernization of traditional medicine has shifted from empirical folklore to evidence-based molecular therapeutics supported by international drug authorities.
Global regulatory agencies, including the US FDA (Botanical Drug Guidance), EMA (HMPC Monographs), and NMPA, now recognize whole-extract medicines provided chemistry, manufacturing, and controls (CMC) meet pharmaceutical parity. Phase II clinical data remains the single most critical inflection point for licensing and institutional investments.
Traditional Chinese Medicine formulas possess documented historical efficacy spanning centuries. MedGence has pioneered the reverse-pharmacology approach: validating classic TCM prescriptions across 83 historical formulas, identifying molecular targets, optimizing downstream bio-availability, and advancing them through standardized Phase II trials.
In mature consumer healthcare markets, dietary supplements require pharmaceutical-grade clinical substantiation to combat commoditization. Conducting small-group human trials or clinical Phase II biomarker evaluations enables functional food and nutraceutical brands to support definitive claims on cognitive health, glucose regulation, and metabolic defense.
Years CRO/CDMO Experience
Dedicated Scientists
Classic Formulas Modernized
Single-Herb Standards Built
Our validated systematic process eliminates downstream execution bottlenecks, taking candidate natural actives from raw plant tissue to audited Phase II regulatory submission.
Systematic quantification of secondary metabolites (polysaccharides, polyphenols, terpenes) across geographical provenances and seasonal harvest schedules to optimize extraction yield and clinical consistency.
Development and validation of robust identification standards using HPLC, HPTLC, and GC chromatographic fingerprinting, establishing identity, purity assays, and strict heavy metal/pesticide limits.
In vitro target-binding assays combined with comprehensive in vivo animal toxicology: LD50, acute toxicity, chronic safety margins, and genotoxicity evaluations to guarantee clinical subject safety.
Multi-center trial management, patient recruitment, placebo formulation development, biomarker tracking, and biostatistical analysis adhering strictly to ICH-GCP guidelines for New Drug Applications (NDA).
Phase II ODM solutions designed to meet stringent global pharmacopeias while delivering optimal patient adherence through specialized final dosage forms.
Supplied as stabilized concentrated liquids, standardized vacuum-dried extract powders, high-potency hydroalcoholic pastes, and supercritical CO2-extracted volatile oils engineered for maximum bioavailability.
Scalable manufacturing of taste-masked oral liquids, enteric-coated capsules, softgels for lipophilic botanical compounds, dual-core tablets, water-soluble micro-granules, and hospital-grade sachets.
Full support for documentation and cross-border filings complying with US FDA Botanical Guidance, European Pharmacopoeia (Ph. Eur.) herbal monographs, and China NMPA New TCM Drug Registration Classifications.
Bridging traditional empirical knowledge with modern biopharmaceutical precision through AI-driven target discovery and advanced continuous processing.
Integrating machine learning models with our repository of hundreds of thousands of research batches to predict target receptor-binding affinity prior to physical assay testing.
Transitioning from traditional batch extraction to automated microfluidic extraction systems, enhancing yield consistency by 25% and dramatically reducing thermal degradation.
Implementing decentralized clinical trial (DCT) methodologies, remote patient biomarker monitoring, and real-time digital pharmacodynamics to accelerate Phase II PoC timelines.
Deploying zero-effluent closed-loop supercritical fluid platforms, reducing environmental footprint while sustaining high active ingredient recovery rates.
In-depth responses for scientific officers, corporate developers, and global procurement teams evaluating an outsourced natural medicine partnership.
Under an Original Design Manufacturer (ODM) contract for Phase II trials, MedGence handles the end-to-end continuum: selecting the optimal botanical chemotype, developing and validating analytical release methods (HPLC/HPTLC), validating preclinical animal safety/efficacy models, formulating clinical-grade investigational medicinal products (IMP), and conducting patient cohort trials to prove clinical efficacy.
We work exclusively on an entrusted research and manufacturing model protected by strict non-disclosure agreements (NDAs). All analytical assays, fractionation parameters, purification temperatures, and clinical data remain the exclusive intellectual property of the commissioning client, ensuring zero leakage of proprietary formulas to competitors.
We address raw botanical variance through multi-point chromatographic fingerprinting and standardized extraction indices. Harvest origin, season, and plant anatomical parts are locked based on comprehensive potency evaluation studies, guaranteeing that every clinical lot matches the precise chromatographic signature of earlier batches.
Yes. Because our scientific team manages both research pilot facilities and scaled contract manufacturing factories, validated extraction, concentration, and drying parameters translate directly into cGMP mass production without needing process re-engineering or risking tech-transfer failures.
Depending on the therapeutic compounds under investigation, our labs implement High-Performance Thin-Layer Chromatography (HPTLC) for identification, High-Performance Liquid Chromatography (HPLC) coupled with DAD/MS for precise quantitative assays, Gas Chromatography (GC) for volatile components, and broad-spectrum chromatographic fingerprinting for complete botanical matrix characterization.
Active pharmaceutical ingredients (API) can be supplied as concentrated liquids, standardized vacuum powders, concentrated pastes, and volatile essential oils. Finished clinical dosage forms encompass oral liquids, hard-shell capsules, softgels, micro-tablets, effervescent granules, and hospital-registered oral suspensions.
Connect with our senior technical scientists to initiate raw-material screening, analytical fingerprinting, or Phase I–IV clinical study designs.
